Bivatuzumab
Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD44 v6 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| ChemSpider |
|
| (verify) | |
It is officially described as "immunoglobulin G1 (human-mouse monoclonal BIWA4 γ1-chain anti-human antigen CD44v6), disulfide with human-mouse monoclonal BIWA4 κ-chain, dimer".[3] Prior to 2002 it was described as targeting CD44 v8.[4]
It has been chemically linked to various radioisotopes for use in radiotherapy for, e.g. inoperable recurrent or metastatic head and neck cancer.[1]
It has also been linked to a cytotoxic drug mertansine to form bivatuzumab mertansine.
References
- Postema; et al. (2003). "Dosimetric Analysis of Radioimmunotherapy with 186Re-Labeled Bivatuzumab in Patients with Head and Neck Cancer".
- Börjesson; et al. (2003). "Phase I Therapy Study with 186Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma".
- WHO Drug Information Vol. 16, No. 3, 2002
- WHO Drug Information, Vol. 15, No. 1, 2001 Recommended INN: List 45. p4
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.